Nakaigawa N, Tomita Y, Tamada S, et al. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. Int J Clin Oncol. 2023;28(3):416–26. https://doi.org/10.1007/s10147-022-02283-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Liao J, Wang L, et al. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms. Front Immunol. 2023;14:1163967. https://doi.org/10.3389/fimmu.2023.1163967.

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO. Cancer. 2022. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed 15 Jan 2025.

Enokida T, Tahara M. Management of VEGFR-targeted TKI for thyroid cancer. Cancers (Basel). 2021;13(21):5536. https://doi.org/10.3390/cancers13215536.

Article  CAS  PubMed  Google Scholar 

Iwasa S, Okita N, Kuchiba A, et al. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503). ESMO Open. 2020;5(4):e000776. https://doi.org/10.1136/esmoopen-2020-000776.

Article  PubMed  PubMed Central  Google Scholar 

Liu Z, Ou W, Li N, et al. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer. 2018;9(10):1285–90. https://doi.org/10.1111/1759-7714.12836.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Chen T, Ding Z, et al. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021;54(4): e13009. https://doi.org/10.1111/cpr.13009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978. https://doi.org/10.3389/fimmu.2018.00978.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaar M, Kamta J, Ait-Oudhia S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. Onco Targets Ther. 2018;11:6227–37. https://doi.org/10.2147/OTT.S170138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67. https://doi.org/10.1056/NEJMra1100265.

Article  CAS  PubMed  Google Scholar 

Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160–78. https://doi.org/10.1016/j.jacc.2015.07.025.

Article  PubMed  Google Scholar 

Hou W, Ding M, Li X, et al. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2021;147(8):2407–20. https://doi.org/10.1007/s00432-021-03521-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. https://doi.org/10.1038/s41569-020-0348-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Totzeck M, Mincu RI, Mrotzek S, et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25(5):482–94. https://doi.org/10.1177/2047487318755193.

Article  PubMed  Google Scholar 

Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403. https://doi.org/10.1038/nrd.2015.17.

Article  CAS  PubMed  Google Scholar 

van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. https://doi.org/10.1016/S0140-6736(12)60651-5.

Article  CAS  PubMed  Google Scholar 

Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15(4):449–66. https://doi.org/10.1007/s11523-020-00738-6.

Article  PubMed  PubMed Central  Google Scholar 

Huang J, Meng L, Yang B, et al. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system. Sci Rep. 2020;10(1):4803. https://doi.org/10.1038/s41598-020-61571-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78. https://doi.org/10.1016/j.jacc.2019.07.056.

Article  CAS  PubMed  Google Scholar 

USFD Administration. FDA adverse event reporting system (FAERS) quarterly data extract files. 2018. Available at: https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/faers-quarterly-data-files-documentation. Accessed 15 Sept 2024.

Liao XL, Ge JQ, Zhu HB, et al. Data mining for hypertension associated with VEGFR-TKIs: based on FAERS database. Chin J Pharmacoepidemiol. 2023;11(32):1201–8. https://doi.org/10.19960/j.issn.1005-0698.202311001.

Article  CAS  Google Scholar 

Goldman A, Bomze D, Dankner R, et al. Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study. Target Oncol. 2021;16(4):471–83. https://doi.org/10.1007/s11523-021-00817-2.

Article  PubMed  Google Scholar 

Sonpavde G, Je Y, Schutz F, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013;87(1):80–9. https://doi.org/10.1016/j.critrevonc.2012.12.006.

Article  PubMed  Google Scholar 

Hall PS, Harshman LC, Srinivas S, et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–8. https://doi.org/10.1016/j.jchf.2012.09.001.

Article  PubMed  Google Scholar 

Gu T, Jiang A, Zhou C, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis. Int J Cancer. 2023;152(3):480–95. https://doi.org/10.1002/ijc.34332.

Article  CAS  PubMed  Google Scholar 

Duggirala HJ, Tonning JM, Smith E, et al. Use of data mining at the Food and Drug Administration. J Am Med Inform Assoc. 2016;23(2):428–34. https://doi.org/10.1093/jamia/ocv063.

Article  PubMed  Google Scholar 

Böhm R, Bulin C, Waetzig V, et al. Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021;87(11):4421–31. https://doi.org/10.1111/bcp.14868.

Article  CAS  PubMed  Google Scholar 

Böhm R, Höcker J, Cascorbi I, et al. OpenVigil–free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012;30(2):137–8. https://doi.org/10.1038/nbt.2113.

Article  CAS  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehad196.

Article  PubMed